Thesis (Ph. D.)--Ohio State University, 2005. / Document formatted into pages; contains xviii, 169 p. Includes bibliographical references. Abstract available online via OhioLINK's ETD Center; full text release delayed at author's request until 2006 March 9.

M.Sc. (Chemistry) / Secondary cancer tumour formation, often called metastasis, remains one of the great scientific challenges in public health. Patients with skeletal metastases have a low survival rate, with great discomforts experienced by the sufferers. Pain, decreased mobility, pathologic bone fractures are some of the effects that these patients have to live with. Significant inroads have been made in using radio pharmaceuticals as a pain palliation treatment for bone metastases. They comprise of a bone seeking phosphonate ligand and a radionuclide. The structural variation of the phosphonate affects to a great extend the effectiveness of the radiopharmaceutical with the greatest shortfall being myelosuppression at high doses. In this study an attempt is made at synthesizing novel bisphosphonates, APDDAM and APDDPE. After several synthetic steps from the protected β-alanine tert butyl ester, the free acid precursor was achieved (as shown in the NMR and elemental analysis) in good yields. Unfortunately the final reaction step to form the bisphosphonate ligand was unsuccessful, with the free acid precursor dissociating in the acidic conditions to form salts. A polymer ligand poly-HEDP was synthesized from its free acid form in relatively low yields. The ligand was used in potentiometric studies with the metal ions Ca(II), Mg(II), Cu(II), Zn(II), Sn(II) and Sn(IV) to evaluate its potential as radiopharmaceutical candidate. The ESTA model formation constants obtained were used in the ECCLES blood plasma model to evaluate the competitive stability of the complexes against biological metal ions and ligands. The Sn(IV)-poly-HEDP complex was shown to be unstable, with a 100 % dissociation. On the other hand the Sn(II)-poly-HEDP showed much improved stability with 100 % of the metal ion remaining bound to the ligand.

Indiana University-Purdue University Indianapolis (IUPUI) / Bone is a common location for breast cancer cell metastasis, and progression of tumor in bone can lead to bone loss and affect human health. Osteocytes have important roles in bone homeostasis and osteogenesis, and their interaction with metastasized cancer cells are known to affect progression of metastasized tumor. However, the potential role of metabolic signaling and actin- cytoskeleton-associated moesin in the interaction of osteocytes and tumor cells remain poorly understood. In this study, we first examined the roles of metabolic signaling, specifically global AMPK modulators and mitochondria-specific AMPK inhibitor (Mito-AIP), as well as mechanical force in beta catenin signaling through interaction between osteocytes and precursor osteoblasts as well as osteocytes and breast cancer cells. We also evaluated the role of metabolic signaling in Rho GTPases including RhoA, Rac1 and Cdc42. We observed that AMPK activator (A769662) and Mito-AMPK stimulated beta catenin translocation to the nucleus, indicating the activation of Wnt signaling, while Mito-AIP did not significantly affect beta catenin activation in osteoblasts. We also observed that osteocyte conditioned medium (CM) treated with Mito-AIP substantially increased beta catenin signaling in osteoblasts, while decreasing beta catenin signaling in breast cancer cells. CM of osteocytes treated with fluid flow increased beta catenin signaling in breast cancer cells. A769662 and Mito-AIP also decreased the activities of RhoA, Rac1, and Cdc42 in cancer cells which are known to regulate cancer cell migration. Additionally, we evaluated the roles of intracellular and extracellular moesin (MSN) protein in well-established oncogenic signaling proteins, such as FAK, Src, and RhoA as well beta catenin signaling. Constitutively active MSN (MSN+) significantly increased FAK and Src activities in cancer cells, but decreased the activity of RhoA. Surprisingly, CM of mesenchymal stem cells treated with MSN+ decreased the activities of FAK, Src, and RhoA, suggesting the inhibitory role of extracellular MSN in tumor-promoting signaling. Our results suggest the distinct role of AMPK signaling, specifically at mitochondria of osteocytes, in the activities of beta-catenin signaling in osteoblasts and breast cancer cells and the distinct role of intracellular and extracellular MSN in these two types of cell.

Breast cancer most commonly metastasizes to the bone, where it perpetuates the vicious cycle leading to osteolytic lesions. This occurs when secreted factors from breast cancer cells disrupt bone homeostasis by deregulation of osteoblast bone formation, and enhance osteoclast bone degradation thereby releasing bone matrix bound growth factors leading to further tumor growth. Although the use of osteoclast targeting agents, such as bisphosphonates and RANK-L inhibitors, are common practice for the treatment of bone metastasis, they have not been shown to increase patient survival. We therefore sought to investigate the role of focal adhesion kinase (FAK), a potential therapeutic target, in the treatment of breast cancer mediated osteolysis. FAK is a non-receptor tyrosine kinase known to directly regulate tumor progression and metastasis; it is also expressed in all of the cell types involved in breast cancer mediated osteolysis. Thus, we hypothesized that the inhibition of FAK would restore normal bone homeostasis, as well as mediate direct anti-tumor activity. FAK depletion resulted in the decrease of expression of several osteolytic factors secreted by breast cancer cells. However, the use of FAK depleted breast cancer conditioned media did not prevent breast cancer mediated osteoclastogenesis in an osteoblast/osteoclast coculture. In monoculture however, using the FAK inhibitor PF-271, we have shown that FAK inhibition leads to increased apoptosis of mature osteoclasts, and their decreased ability to degrade mineralized bone matrix, perhaps in part due to reduced expression of lytic factors such as tartrate resistant acid phosphatase and cathepsin K. Further, FAK inhibition in osteoblast monoculture led to a decrease in their ability to express the maturation factor alkaline phosphatase, and also inhibited their ability to induce mineralization. This inhibition may be due in part to the specific effects of FAK inhibition using PF-271, which may result in decreased levels of p53 in treated osteoblasts. These results suggests that the pharmacological inhibition of FAK can effect all three cell types involved in the vicious cycle of bone metastasis, and as such could be a beneficial therapeutic for patients with bone metastasis resulting in prevention of bone degradation along with direct inhibition of tumor growth. However, it may require further evaluation in animal models to determine if observed effects on osteoblast activity in vitro also occurs in vivo with possible detrimental effects on restoration of damaged bone.

Οι οστικές μεταστάσεις εμφανίζονται συχνά κατά την εξέλιξη του καρκίνου, συχνότερα σε συγκεκριμένου τύπου καρκίνους όπως ο καρκίνος του μαστού και του προστάτη και λιγότερο συχνά σε άλλους κακοήθεις όγκους όπως του πνεύμονα και του νεφρού. Περισσότερο από 50% των ασθενών με προχωρημένο καρκίνο του μαστού και του προστάτη εμφανίζουν οστικές μεταστάσεις, ενώ άπαξ και ο όγκος προσβάλλει τα οστά η νόσος καθίσταται στην πλειονότητα των περιπτώσεων μη ιάσιμη. Τα συμπτώματα από την προσβολή του σκελετού περιλαμβάνουν μεταξύ άλλων πόνο, παθολογικά κατάγματα, υπερασβεστιαιμία, και εκδηλώσεις από τα νεύρα Οι υπάρχουσες θεραπευτικές παρεμβάσεις είναι παρηγορητικές καθιστώντας επιτακτική την καλύτερη κατανόηση των υποκείμενων μηχανισμών, η οποία θα επιτρέψει την ανακάλυψη νέων θεραπειών. Ο οστεοτροπισμός συγκεκριμένων νεοπλασιών είχε απασχολήσει από πολύ νωρίς τους επιστήμονες δίνοντας τις βάσεις για τις πιο σύγχρονες προσεγγίσεις. Τα όλο αυξανόμενα δεδομένα υπογραμμίζουν ότι ο σχηματισμός των οστικών μεταστάσεων δεν αποτελεί μια απλή διαδικασία μετανάστευσης των καρκινικών κυττάρων στην μεταστατική εστία. Αντίθετα συνίσταται από ένα σύνολο πολύπλοκων διεργασιών στο οποίο συμμετέχουν τα καρκινικά κύτταρα και τα κύτταρα του ξενιστή. Αρχικά εμφανίζεται επέκταση της πρωτοπαθούς εστίας εις βάρος των παρακείμενων κυττάρων και του στρώματος του ιστού. Στη συνέχεια η μείωση της έκφρασης μορίων προσκόλλησης στην επιφάνεια των καρκινικών κυττάρων οδηγεί σε αποκοπή τους από την πρωτοπαθή εστία και σε διήθηση του ιστού και των αγγειακών τοιχωμάτων. Ακολουθεί η μετανάστευσή τους μέσω της αιματικής ροής ενώ με την βοήθεια κατάλληλων μορίων διαφεύγουν της εποπτείας του ανοσοποιητικού συστήματος και καταλήγουν στα κολποειδικά τριχοειδή του μυελού όπου αγκυροβολούν και αναπτύσσονται. Στη συνέχεια διηθούν και πάλι τα αγγειακά τοιχώματα για να εγκατασταθούν πλέον στον μυελό των οστών όπου και θα αναπτυχθεί η δευτεροπαθής εστία με μηχανισμούς που θα αναλυθούν. / -

Bisphosphonates (BPs) have been used clinically as anti-resorptive/cancer agents with confounded clinical outcomes and uncertain/conflicting biological understanding. This study was designed to evaluate the impact of clinically used anti-resorption drug alendronate (ALN) on cancer-bone metastasis and bone biology using novel 3D cancer-bone interaction model systems. To test the effects of ALN on the cancer-bone metastasis/interactions and bone biology we have utilized a novel 3D Co-cultures of live mouse neonatal calvarial bone organs with oral squamous cancer cells in a roller tube model systems (Curtin et al, 2012) in the absence and presence of ALN. These model systems under bone resorption and formation conditions were evaluated by chemical, biochemical, and histological analyses of the used media and calvarial bones. At the end of 8 days, the calvarial bones co-cultured with oral cancer cell lines in the absence and presence of ALN were processed for histological observations, TRAP and ALP enzyme activities, and neutral red staining. These studies were complemented by the effects of ALN on oral cancer cells under 2D classic cell culture conditions. In 3D-bone organ cultures under resorption conditions, oral cancer cells induce differentiation of osteoclasts and bone resorption and inclusion of ALN inhibited cancer-induced bone resorption. However, in both bone resorption and formation models the oral cancer cells colonized the bone and while treatment with ALN inhibits bone resorption, no effect on bone colonization was evident. Contrary to those under 2D cell culture conditions exposure to ALN of confluent and non-confluent oral cancer cells in the absence of live bone impacted oral cancer cells significantly in a dose dependent manner. Our studies using live bone organ cultures with oral cancer cells under specific dissociated bone remodeling stages, viz., resorption or formation only, revealed major and significant biological events which led to the conclusions that: (a) In the absence of bone in 2D cultures oral cancers are sensitive to ALN treatment whereas in the 3D live bone microenvironment tumors are resistant to ALN drug therapy, and (b) oral cancer-bone metastasis is independent of bone remodeling stage.

OBJECTIVE: To determine the effect of clinically used zoledronate (ZOL) and docetaxel on breast cancer cells and bone biology under both bone remodeling stages and the rate of tumor dissemination and state of dormancy. METHODS: The effect of clinically used zoledronate (ZOL) was examined on MDA-MB-231 and MDA-BO cells in a roller tube system under bone resorption and formation conditions. Three groups; calvaria alone, calvarial co-cultured with tumor cells, and calvaria with tumor cells treated with four repeat doses of 2 µM of ZOL were cultured for 8, 14 and 20 days. The formation groups were supplemented with 150 µg/ml ascorbic acid. Cell counts were performed on trypsinized calvaria harvested at 2, 8 and 14 days. Media was changed every 2 days and the changed media was re-seeded in a 24-well for 20 days. To test the impact of chemotherapy agents on cancer-bone metastasis the effect of 10 µM of docetaxel was tested on breast cancer cells under formation and resorption conditions using the above design. Tumor burden was assessed at 8 days. RESULTS: Tumor burden: no statistically significant difference between ZOL treated and untreated groups under resorption and formation conditions in both cell lines. Exposure to docetaxel revealed that ~30% of the cells were affected by chemotherapy in formation model, while ~70% was affected in resorption model in both cell types. Dissemination model: the dissemination rate for MDA and BO cells under formation condition is significantly less than for resorption conditions. Fluorescent microscopy: MDA and BO tumor-calvaria were treated with Ki 67 antibody showed that under bone resorption conditions the cancer-bone cells colony were predominantly in proliferation stage while under formation conditions cancer cells were in dormancy. Confocal microscopy: observation confirmed the relation of the mode of cancer cell attachment to bone endosteal cell layer with the dormancy and cell proliferation states. CONCLUSIONS: Both cancer cell lines showed resistance to ZOL under formation and resorption conditions. Drug resistance to docetaxel was more evident under formation condition, where cells are dormant and not proliferating. The dissemination rate is significantly higher in resorption condition, suggesting that cells in formation are dormant with lower dissemination rate. / 2019-07-23T00:00:00Z

Breast cancer shows a high affinity towards the bone, causing bone-related complications leading to poor clinical prognosis. Approximately 80% of breast cancer patients die within five years after primary cancer has metastasized to the bones. The tumor stage strongly influences the survival rates of patients with breast cancer that has spread to bone at the time of diagnosis. There are currently no effective therapeutics available for bone metastases due to the failure of animal models and the scarcity of human bone metastasized samples, as most patients with advance stages of cancer are already in palliative care. Therefore, it is imperative to develop translational models to elucidate disease mechanisms at the cellular and molecular level. Here, we report the development of tissue-engineered nanoclay-based bone-mimetic three-dimensional (3D) in vitro model for studying later stages of cancer pathogenesis at the metastatic bone site using osteogenically-differentiated human mesenchymal stem cells (MSCs) and human breast cancer cells (MDA-MB-231 and MCF-7). This 3D model provides an ideal microenvironment suitable for cell-cell and cell-matrix interactions while retaining the behavior of breast cancer cells with different metastatic potential along with mimicking mesenchymal to epithelial transition (MET) of breast cancer cells. Sequential cultures of MSCs with MCF-7 gave rise to tumoroids, while sequential cultures of MSCs with MDA-MB-231 formed disorganized clusters of cells with poor cell-cell adhesion. We further evaluated how cancer-derived factors and cytokines affect bone leading to up to metastasis and conferring drug resistance, respectively. Results showed that Wnt/β-catenin and interleukin-6 (IL-6) mediated IL-6/STAT3 pathways are responsible for bone-related complications and conferring drug resistance, respectively. Furthermore, we have utilized the 3D in vitro model to develop methods for non-invasive and rapid prediction of cancer progression using various biophysical techniques such as spectroscopy and nanoindentation. Spectroscopy methods showed significant contributions of proteins, lipids, and nucleic acids, while the nanoindentation method showed F-actin mediated softening of cancer cells during cancer progression at the metastatic bone site, respectively. Collectively, 3D in vitro model provides an ideal platform for studying the molecular mechanism of breast cancer progression at the metastatic bone site, drug development, and discovery of biomarkers for cancer progression.

京都大学 / 新制・課程博士 / 博士(医学) / 甲第24473号 / 医博第4915号 / 新制||医||1062(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 溝脇 尚志, 教授 黒田 知宏, 教授 花川 隆 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

No description available.